ObjectiveTo investigate the reporting and methodological quality of systematic reviews/ meta-analyses conducted by hospital pharmacists in China, so as to improve the quality of systematic reviews/ meta-analyses in this field. MethodsThe literatures were retrieved from CNKI, WanFang Data, VIP, CBM, CMCI, PubMed, EMbase, The Cochrane Library from the establishment date to March 17th, 2016. According to the inclusive and exclusive criteria, authors independently screened and extracted the published information. Reporting and methodological quality of included reviews were evaluated by PRIMSA statements and AMSTAR checklists. Data analysis was conducted by using Excel 2013 software and SPSS 20.0 software. ResultsOne thousand and eighteen systematic reviews/ meta-analyses were included, including 871 Chinese literatures and 147 English literatures. The average score of PRIMSA was 18.41±2.84, and the average score of AMSTAR was 7.38±1.28. The main problems of PRIMSA were structured summary, objectives, protocol and registration, additional analyses and funding. The main problems of AMSTAR were priori design, status of publication and list of studies (included and excluded). Univariate analysis showed that some factors could improve the quality of methodology and reporting, including studies in English (P<0.000 1), published after checklists' (P<0.000 1), hospital in higher-level (P<0.000 1), illuminating the funding or interest conflict (P<0.000 1). Pearson analysis indicated that linear correlation were detected between PRISMA scores and AMSTAR scores (P<0.000 1), as well as citations and AMSTAR scores (P=0.045). ConclusionEvidenced-based pharmacy in hospital has developed rapidly, the quality of methodology and reporting have increaseed year by year, but further improvement should be considered in different aspects. The methods to evaluate the clinical application of these systematic reviews/ meta-analyses should be developed in the future.
Objective To investigate the current status of systematic reviews/meta-analyses published by pharmacists in hospital in China by using bibliometric analysis and assessing the methodological quality of these studies. Methods The literatures were searched from CNKI, WanFang Data, VIP, CBM, CMCI, PubMed, EMbase, The Cochrane Library (Issue 2, 2016) from the establishment to March 17th, 2016. According to the inclusive and exclusive criteria, the authors independently screened literature and extracted the data. Methodology quality and reporting quality were evaluated by using AMSTAR tool and PRIMSA statement. Data analysis was conducted by using Excel 2013 and SPSS 20.0 software. Results A total of 1 018 systematic reviews/meta-analyses were included of which 871 were published in Chinese and 147 were in English. The published literature increased year by year, as well as the reporting quality and methodological quality. All of the included studies were published in 146 Chinese journals and 97 English journals. The authors were from 308 hospitals of 27 provinces. Drug effectiveness and drug safety were mainly assessed, and western medicine was the main category. Most of these studies were focused on anti-tummor drugs. Conclusion Evidenced-based drug evaluation by hospital pharmacists in China is rapidly increasing as well as the methodological quality and reporting quality, however, the development is unbalanced in China, and evidence-based medicine should be further promoted in the field of hospital pharmacy.
The protocol of rational use of oral H1 receptor antagonists in children: a clinical practice guideline primarily introduces key methods, processes and precautions of the guideline to standardize and guarantee the formulation of this evidence-based guideline. Referring to the World Health Organization Guidelines Development Manual, the guideline will be conducted according to the following steps, which involves the establishment of project group; registration (IPGRP-2020CN110); declaration of interest and funding support; identification of the clinical issues and outcomes; evidence retrieval, assessment, synthesis and utilization; investigation of patients’ preferences and values; development, external review and revision of recommendations; guideline release, dissemination and update.
Clinical pharmacy practice guidelines have developed rapidly in recent years. They provide a series of recommendations for optimizing drug treatment management and improving pharmaceutical care appropriateness and are widely employed in clinical practice. Based on literature review and the experience of guideline development, this paper summarized the meaning, formulation methods, formulation status, and registration of clinical pharmacy practice guidelines, and provided suggestions for the development of guidelines.
Oral H1-antihistamines are one of the most commonly prescribed drug categories in the treatment of allergic diseases in children. However, its rational application still lacks sufficient evidence and pharmaceutical guidance, making its clinical use risky. Based on the best available evidence, expert experience, and the willingness of patients' families, the guideline development panel developed this guideline, using the grading of recommendations assessment, development and evaluation (GRADE) approach. The guidelines developed 19 recommendations in 8 domains, covering the therapeutic status of oral H1-antihistamines in pediatric allergic diseases, age range, dose, duration of treatment, adjustment in the presence of hepatic and renal insufficiency, drug interactions, adverse effects and adherence. As a result, this guideline helped to standardize and guide the rational use of oral H1-antihistamines in pediatric allergic diseases.